10.66
0.24 (2.30%)
| Previous Close | 10.42 |
| Open | 10.51 |
| Volume | 6,031,420 |
| Avg. Volume (3M) | 4,758,635 |
| Market Cap | 7,606,432,256 |
| Price / Sales | 71.92 |
| Price / Book | 1.59 |
| 52 Weeks Range | |
| Earnings Date | 28 May 2025 - 2 Jun 2025 |
| Profit Margin | -95.14% |
| Operating Margin (TTM) | -2,921.72% |
| Diluted EPS (TTM) | -1.00 |
| Quarterly Revenue Growth (YOY) | -42.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.81% |
| Current Ratio (MRQ) | 37.91 |
| Operating Cash Flow (TTM) | -775.34 M |
| Levered Free Cash Flow (TTM) | -654.62 M |
| Return on Assets (TTM) | -11.62% |
| Return on Equity (TTM) | -14.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Roivant Sciences Ltd. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | -1.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.90 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 27.67% |
| % Held by Institutions | 80.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Toms Capital Investment Management Lp | 31 Dec 2024 | 5,885,000 |
| 52 Weeks Range | ||
| Median | 18.00 (68.86%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 Apr 2025 | 18.00 (68.86%) | Buy | 10.04 |
| 11 Feb 2025 | 18.00 (68.86%) | Buy | 10.49 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PULIK RICHARD | - | 11.19 | -1,653 | -18,497 |
| Aggregate Net Quantity | -1,653 | |||
| Aggregate Net Value ($) | -18,497 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 11.19 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PULIK RICHARD | Officer | 28 Apr 2025 | Disposed (-) | 1,653 | 11.19 | 18,497 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |